Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310381 | 0.95 | CACNA2D1 (0.51) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3312481 | 0.93 | CACNA2D1 (0.47) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3344733 | 0.84 | CACNA2D1 (0.54) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL5507830 | 0.84 | CACNA2D1 (0.54) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3310370 | 0.82 | CACNA2D1 (0.60) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Cadaverine Tartrate SCHEMBL3137755 | 0.80 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Cadaverine Tartrate SCHEMBL3137768 | 0.80 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Cadaverine Tartrate SCHEMBL2450635 | 0.80 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Cadaverine Tartrate SCHEMBL3280551 | 0.80 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3312476 | 0.79 | CACNA2D1 (0.54) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258871-A1 | (S)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-11-16 | — | — | US | claimed |
| US-20060258871-A1 | (S)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-11-16 | — | — | US | disclosed |
| US-20060258871-A1 | (S)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258871-A1 | (S)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof | DNTT, PNMT, AANAT | CACNA2D1 771/4885SLC6A2 20/4885SLC6A4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.